99 related articles for article (PubMed ID: 8602402)
1. Measurement of prostate-specific membrane antigen in the serum with a new antibody.
Murphy GP; Tino WT; Holmes EH; Boynton AL; Erickson SJ; Bowes VA; Barren RJ; Tjoa BA; Misrock SL; Ragde H; Kenny GM
Prostate; 1996 Apr; 28(4):266-71. PubMed ID: 8602402
[TBL] [Abstract][Full Text] [Related]
2. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
[TBL] [Abstract][Full Text] [Related]
3. Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients.
Holmes EH; Greene TG; Tino WT; Boynton AL; Aldape HC; Misrock SL; Murphy GP
Prostate Suppl; 1996; 7():25-9. PubMed ID: 8950359
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific membrane antigen and its truncated form PSM'.
Mlcochová P; Barinka C; Tykvart J; Sácha P; Konvalinka J
Prostate; 2009 Apr; 69(5):471-9. PubMed ID: 19107881
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
Horoszewicz JS; Kawinski E; Murphy GP
Anticancer Res; 1987; 7(5B):927-35. PubMed ID: 2449118
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.
Liu H; Moy P; Kim S; Xia Y; Rajasekaran A; Navarro V; Knudsen B; Bander NH
Cancer Res; 1997 Sep; 57(17):3629-34. PubMed ID: 9288760
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH
Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413
[TBL] [Abstract][Full Text] [Related]
8. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
Kinoshita Y; Kuratsukuri K; Newman N; Rovito PM; Kaumaya PT; Wang CY; Haas GP
Prostate Cancer Prostatic Dis; 2005; 8(4):359-63. PubMed ID: 16172607
[TBL] [Abstract][Full Text] [Related]
9. Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography.
Liu T; Toriyabe Y; Berkman CE
Protein Expr Purif; 2006 Oct; 49(2):251-5. PubMed ID: 16815035
[TBL] [Abstract][Full Text] [Related]
10. Constitutive and antibody-induced internalization of prostate-specific membrane antigen.
Liu H; Rajasekaran AK; Moy P; Xia Y; Kim S; Navarro V; Rahmati R; Bander NH
Cancer Res; 1998 Sep; 58(18):4055-60. PubMed ID: 9751609
[TBL] [Abstract][Full Text] [Related]
11. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2010 Sep; 70(12):1286-94. PubMed ID: 20623630
[TBL] [Abstract][Full Text] [Related]
12. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.
Israeli RS; Powell CT; Fair WR; Heston WD
Cancer Res; 1993 Jan; 53(2):227-30. PubMed ID: 8417812
[TBL] [Abstract][Full Text] [Related]
13. [A monoclonal antibody that reacts with an antigen on both normal and malignant prostate cells].
Dou L; Yu L; Xing N; Ding Y; Deng F; Guo Y
Zhonghua Wai Ke Za Zhi; 1998 Apr; 36(4):234-6, 44. PubMed ID: 11825376
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies to human prostate and bladder tumor-associated antigens.
Starling JJ; Sieg SM; Beckett ML; Schellhammer PF; Ladaga LE; Wright GL
Cancer Res; 1982 Aug; 42(8):3084-9. PubMed ID: 7046915
[TBL] [Abstract][Full Text] [Related]
15. Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector.
Kuratsukuri K; Wang CY; Sone T; Nishisaka N; Jones RF; Haas GP
Eur Urol; 2002 Jul; 42(1):67-73. PubMed ID: 12121733
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5.
Lopes AD; Davis WL; Rosenstraus MJ; Uveges AJ; Gilman SC
Cancer Res; 1990 Oct; 50(19):6423-9. PubMed ID: 1698122
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of rat monoclonal antibodies to denatured mouse angiotensin-converting enzyme.
Balyasnikova IV; Metzger R; Sun ZL; Berestetskaya YV; Albrecht RF; Danilov SM
Tissue Antigens; 2005 Mar; 65(3):240-51. PubMed ID: 15730516
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a monoclonal antibody, KR-P8, that detects a new prostate-specific marker.
Raynor RH; Hazra TA; Moncure CW; Mohanakumar T
J Natl Cancer Inst; 1984 Sep; 73(3):617-25. PubMed ID: 6206270
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody 7E11.C5 staining of viable LNCaP cells.
Barren RJ; Holmes EH; Boynton AL; Misrock SL; Murphy GP
Prostate; 1997 Jan; 30(1):65-8. PubMed ID: 9018338
[TBL] [Abstract][Full Text] [Related]
20. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
